SCHEMBL270295

SCHEMBL270295

CC[CH]c1ccco1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28304721 0.98
SCHEMBL28235743 0.95 ALDH1A1 (0.48)
SCHEMBL270347 0.84
SCHEMBL921218 0.81 ALDH1A1 (0.48)
SCHEMBL10745935 0.79
SCHEMBL14416288 0.79
SCHEMBL256707 0.79
SCHEMBL499995 0.79 ALDH1A1 (0.50)
SCHEMBL10431713 0.78
SCHEMBL183492 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110082441-A The method and kit of detection disabling essence 中国检验检疫科学研究院 2019-08-02 CN claimed
CN-109985626-A For the method for furfural liquid-phase hydrogenatin ethyl furfuryl group ether and the preparation method of catalyst and catalyst 天津大学 2019-07-09 CN claimed
EP-2045251-B1 COMPOUND THAT CAN INHIBIT UBC13-UEV INTERACTIONS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC USES CONSEJO SUPERIOR INVESTIGACION (ES) 2015-11-18 EP claimed
US-8785430-B2 Compound that can inhibit UBC13-UEV interactions, pharmaceutical compositions and therapeutic uses CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) 2014-07-22 US claimed
US-20130237529-A1 COMPOUND THAT CAN INHIBIT UBC13-UEV INTERACTIONS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC USES CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS 2013-09-12 US claimed
US-8252786-B2 Compound that can inhibit UBC13-UEV interactions, pharmaceutical compositions and therapeutic uses CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) 2012-08-28 US claimed
US-20110160189-A1 COMPOUND THAT CAN INHIBIT UBC13-UEV INTERACTIONS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC USES CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) 2011-06-30 US claimed
EP-2045251-A1 COMPOUND THAT CAN INHIBIT UBC13-UEV INTERACTIONS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC USES Consejo Superior de Investigaciones Cientificas (ES) 2009-04-08 EP claimed
EP-0718281-B1 CYCLOHEXANEDIUREA DERIVATIVE AND PROCESS FOR PRODUCING THE SAME NISSIN FOOD PRODUCTS LTD (JP) 2001-06-27 EP claimed
CN-108948019-B Focal adhesion kinase inhibitors and uses thereof 广东东阳光药业有限公司 2022-07-08 CN disclosed
EP-3750892-A1 NOVEL 5-CYCLOPROPYL-FURO[3,4-C]PYRIDINE-3,4(1H,5H)-DIONE 1,1' SUBSTITUTED DERIVATIVES AND THEIR USES Yerevan State University (AM) 2020-12-16 EP disclosed
CN-110082441-A The method and kit of detection disabling essence 中国检验检疫科学研究院 2019-08-02 CN disclosed
CN-110003150-A A method of utilizing Furfural Production from Xylose 南开大学 2019-07-12 CN disclosed
CN-109985626-A For the method for furfural liquid-phase hydrogenatin ethyl furfuryl group ether and the preparation method of catalyst and catalyst 天津大学 2019-07-09 CN disclosed
US-4472300-A ANTIMICROBIAL FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1984-09-18 US disclosed
US-4472309-A ANTIMICROBIAL FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1984-09-18 US disclosed
US-4304718-A ANTIBIOTICS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1981-12-08 US disclosed
US-4264498-A REACTED WITH AN ACID, ITS ACID HALIDE, OR ANHYDRIDE IN THE PRESENCE OF BORON TRIHALIDE AND AN ORGANIC BASE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1981-04-28 US disclosed
US-4207234-A 4-Unsubstituted azetidinone derivatives and process for preparation thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1980-06-10 US disclosed
US-4181800-A ANTIBIOTICS FROM SUBSTITUTED PERHYDRO-S-TRIAZINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1980-01-01 US disclosed